Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 76Triple Negative Breast Neoplasms 12Ovarian Neoplasms 7Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms, Male 4Pancreatic Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Kidney Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Melanoma 1

Interventions

liposomal doxorubicin 1Vinorelbine 1Surveys and Questionnaires 1Prophylactic Mastectomy 1Docetaxel 1Cognitive Behavioral Therapy 1Cephalexin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Predisposition to Disease × liposomal doxorubicin × Breast × Clear all
NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡